Ifinatamab deruxtecan

Daiichi Sankyo and Merck's ifinatamab deruxtecan shows 54.8% objective response rate at 12 mg/kg in pretreated extensive-stage small cell lung cancer patients, leading to its selection for phase 2 and 3 trials.

Ifinatamab deruxtecan shows promising objective response rates in pretreated extensive-stage small cell lung cancer patients in the IDeate-Lung01 phase 2 trial, with confirmed ORR of 54.8% and 26.1% in 12 mg/kg and 8 mg/kg cohorts, respectively.

Merck discontinues Phase 3 KeyVibe-008 trial evaluating a fixed-dose combination of vibostolimab and pembrolizumab in extensive-stage small cell lung cancer (ES-SCLC) patients due to meeting pre-specified futility criteria for overall survival (OS). Patients in the combination arm experienced higher rates of adverse events (AEs) and immune-related AEs compared to the control arm. Ongoing comprehensive analysis and further clinical development program expansions are noted.

The IDeate-Lung02 Phase 3 trial evaluating ifinatamab deruxtecan in relapsed small cell lung cancer has initiated, with the first patient dosed.